RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. filed a Schedule 13D with the SEC on November 6, 2026, disclosing a combined beneficial ownership of 7,429,758 shares of Bambusa Therapeutics, Inc. common stock following the company's initial public offering and subsequent open-market purchases on October 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: The reporting persons collectively hold 7,429,758 shares of Bambusa Therapeutics common stock, representing 14.6% of the class.
  • Fund-level holdings: RA Capital Healthcare Fund, L.P. directly holds 5,933,787 shares (11.6% of the class); RA Capital Nexus Fund III, L.P. holds an additional 1,495,971 shares.
  • IPO participation: The Fund and Nexus Fund III together purchased 2,335,109 and 164,891 shares, respectively, from underwriters at the IPO price of $16.00 per share, for a combined purchase price of $40,000,000.
  • Open-market purchases on October 30, 2026: The Fund bought 189,909 shares at a weighted-average price of $14.23 per share and 263,911 shares at a weighted-average price of $14.92 per share.
  • Pre-IPO preferred stock: The aggregate purchase price of preferred stock acquired before the IPO was $27,777,749, covering Series A-1 and Series A-2 preferred shares that converted 1-to-1 into common stock at IPO closing on November 2, 2026.
  • Stock split: Share counts reflect a 1.54485-for-1 forward stock split of Bambusa Therapeutics' outstanding capital stock effected on October 23, 2026.

RA Capital's Position in Bambusa Therapeutics: IPO, Conversion, and Open-Market Activity

According to the Schedule 13D filing, RA Capital Management, L.P. serves as investment adviser for both RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., and may be deemed a beneficial owner of securities held by those funds. The filing states that each fund has delegated to RA Capital the sole power to vote and dispose of all securities in its portfolio, and that this delegation may not be revoked on less than 61 days' notice. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah are also deemed beneficial owners of the reported shares, though the filing notes that RA Capital, Dr. Kolchinsky, and Mr. Shah "disclaim beneficial ownership of the securities reported in this Schedule 13D other than for the purpose of determining their obligations under Section 13(d) of the Act."

The filing discloses that prior to Bambusa Therapeutics' IPO, the Fund purchased 2,844,910 shares of Series A-1 preferred stock and 299,948 shares of Series A-2 preferred stock, while Nexus Fund III purchased 1,278,148 shares of Series A-1 and 52,932 shares of Series A-2 preferred stock. These figures reflect the 1.54485-for-1 forward stock split effected October 23, 2026. Upon the IPO closing on November 2, 2026, all preferred shares converted into common stock on a 1-to-1 basis. The Fund and Nexus Fund III also purchased additional common shares directly from the underwriters at the $16.00 IPO price.

The triggering event for this Schedule 13D filing was October 30, 2026, when the Fund made open-market purchases totaling 453,820 shares across two tranches: 189,909 shares at prices ranging from $13.61 to $14.58 per share, and 263,911 shares at prices ranging from $14.65 to $15.00 per share. The filing states all purchases were funded by working capital of the Fund and Nexus Fund III. Shared voting and dispositive power over the aggregate 7,429,758 shares is reported identically for RA Capital, Dr. Kolchinsky, and Mr. Shah, with sole voting and sole dispositive power listed at zero for each.

What Was Disclosed

The Schedule 13D filed November 6, 2026 reports that RA Capital Management and affiliated persons beneficially own 7,429,758 shares, or 14.6%, of Bambusa Therapeutics common stock, acquired through pre-IPO preferred stock purchases, IPO participation, and open-market transactions on October 30, 2026.